Continuous Glucose Monitoring Improves Glycemic Control in Non-Insulin-Treated Type 2 Diabetes, Suggests Review
A recent systematic review and meta-analysis published in Diabetes, Obesity and Metabolism in 2025 demonstrates that unlocking the power of continuous glucose monitoring (CGM) can substantially optimize glycemic control in non-insulin-treated type 2 diabetes, driving a clinically significant 0.37% reduction in HbA1c alongside an impressive 8.84% increase in time in target range.
Historically, continuous glucose monitoring (CGM) research and clinical guidelines have focused primarily on insulin-treated populations, leaving an evidence gap for those on alternative therapies. To address this void, Dr. Ronnie Aronson and an expert panel synthesized current data to establish practical, evidence-based recommendations for integrating CGM into the daily management of noninsulin-treated adults.
Therefore, the systematic review and meta-analysis of eight randomized controlled trials evaluated continuous glucose monitoring (CGM) versus standard care in 541 noninsulin-treated patients with type 2 diabetes. By strictly excluding insulin users and observational data, the analysis rigorously assessed CGM's true clinical impact on core glycemic metrics, including time in range, time above range, and time below range.
Key Clinical Findings of the Review Includes:
HbA1c Reduction: Meta-analysis demonstrated that continuous sensors significantly diminished overall hemoglobin levels by a weighted mean difference of 0.37% compared to traditional capillary testing.
Target Attainment: Review reported a substantial 8.84% enhancement in the exact time patients successfully spent within their optimal glucose range versus usual care.
Hyperglycemia Mitigation: Analysis confirmed a marked 8.14% reduction in the duration participants remained dangerously above their therapeutic glucose target compared to baseline methods.
Hypoglycemia Stability: Evaluation indicated no significant shifts in the time spent below range compared to controls, highlighting safety without precipitating low glucose events.
The results suggest that deploying continuous sensing technologies in non-insulin-treated individuals is strongly associated with profound improvements in key glycemic outcomes—such as the nearly 9% increase in time in target range—complementing notable non-glycemic benefits like heightened patient satisfaction, reduced distress, and minimized healthcare resource utilization.
Thus, the study concludes clinicians should consider incorporating these real-time or intermittently scanned monitors as a supportive adjunct for lifestyle modification and treatment intensification in their noninsulin-dependent patients experiencing suboptimal glycemic control.
While the findings are highly promising, the relatively small sample sizes, short follow-up durations, and open-label designs of the included trials pose certain generalizability limitations. Consequently, there remains a gentle need for larger, longer-term research to further illuminate the enduring impact of this technology on chronic complications without detracting from its current clinical value.
Reference
Aronson R, Abitbol A, Bajaj HS, et al. Continuous glucose monitoring in noninsulin-treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2025;27(11):6220‐6242.
